Previous research found vorinostat in combination with Bcl-2 and Bcl-xL inhibitor ABT-263 shows strongly cooperate to overcome heterogeneity associated with response to HDACi across diverse tumour cell types [38]. Here, BCL2 is linked to neoplasm.